Clinical Trial Update: Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the effects of single doses of MK2637 and dextromethorphan on cerebral cortex excitability in schizophrenia. The study status is Co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Dextromethorphan (dextromethorphan)
• MK2637

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED